Organon & Co.
NYSE:OGN · New York Stock Exchange
+$0.01 today
Vol 2.14M · Avg 8.57M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:OGN · Revenue to Net Income
Key Ratios
Analysis
$6.2B of revenue converted into $246.0M of net income for the selected period. Gross margin is 53.1% and net margin is 3.9%, showing how much revenue survives after costs and taxes. EPS is $0.93, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2B -2.9% | $6.4B +2.2% | $6.3B +1.4% | $6.2B -2.1% | $6.3B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.9B +6.2% | $2.7B +6.9% | $2.5B +9.6% | $2.3B -3.7% | $2.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.4B -9.5% | $3.7B -0.9% | $3.7B -3.4% | $3.9B -1.1% | $3.9B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 54.1% -3.9pp | 58.0% -1.8pp | 59.8% -3.0pp | 62.8% +0.6pp | 62.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $366.0M -22.0% | $469.0M -11.2% | $528.0M +12.1% | $471.0M +6.3% | $443.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $1.7B -2.8% | $1.8B -7.0% | $1.9B +11.1% | $1.7B +2.2% | $1.7B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $2.1B -6.4% | $2.2B -7.9% | $2.4B +11.3% | $2.2B +8.4% | $2.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $353.3M +27.6% | $277.0M +17.4% | $236.0M +11.3% | $212.0M +8.7% | $195.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.3B -20.1% | $1.6B +11.7% | $1.4B -18.2% | $1.8B -11.4% | $2.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 20.6% -4.4pp | 25.1% +2.1pp | 22.9% -5.5pp | 28.4% -3.0pp | 31.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.3B -13.5% | $1.5B +12.0% | $1.3B -22.2% | $1.7B -11.0% | $1.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 20.7% -2.5pp | 23.2% +2.0pp | 21.2% -6.4pp | 27.6% -2.8pp | 30.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $504.0M -3.1% | $520.0M -1.3% | $527.0M +24.9% | $422.0M +63.6% | $258.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$860.0M -26.7% | -$679.0M -3.8% | -$654.0M -12.2% | -$583.0M -51.0% | -$386.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $425.0M -47.3% | $807.0M +19.9% | $673.0M -40.0% | $1.1B -26.6% | $1.5B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 6.8% -5.8pp | 12.6% +1.9pp | 10.7% -7.4pp | 18.2% -6.1pp | 24.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $238.0M +517.5% | -$57.0M +83.7% | -$350.0M -270.7% | $205.0M +15.2% | $178.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $187.0M -78.4% | $864.0M -15.5% | $1.0B +11.6% | $917.0M -32.1% | $1.4B | $4.9B | $4.8B | $4.7B |
| Net Margin | 3.0% -10.5pp | 13.5% -2.8pp | 16.3% +1.5pp | 14.9% -6.6pp | 21.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 -78.6% | $3 -16.2% | $4 +11.1% | $4 -32.3% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 -78.4% | $3 -16.5% | $4 +11.1% | $4 -32.6% | $5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $259.5M +1.0% | $257.0M +0.7% | $255.2M +0.5% | $254.1M +0.2% | $253.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $260.8M +0.6% | $259.2M +1.1% | $256.3M +0.4% | $255.2M +0.6% | $253.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.74B
Avadel Pharmaceuticals plc
AVDL
$2.12B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.10B
Select Medical Holdings Corporation
NYSE:SEM
$2.05B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.94B
Nuvation Bio Inc.
NYSE:NUVB
$1.91B
Pediatrix Medical Group, Inc.
NYSE:MD
$1.90B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.27B
Alvotech
NASDAQ:ALVO
$1.22B
Tilray Brands, Inc.
NASDAQ:TLRY
$560.02M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does OGN generate?
Organon & Co. (OGN) reported $6.22B of revenue in fiscal 2025.
Is OGN profitable?
Organon & Co. (OGN) reported $187.00M of net income, with a net margin of 3.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.